Home > Search Results: Allan, J N.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
12 p, 1.1 MB Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL : primary analysis of the CAPTIVATE FD cohort / Tam, Constantine S (University of Melbourne) ; Allan, John N (Weill Cornell Medicine) ; Siddiqi, Tanya (City of Hope National Medical Center) ; Kipps, Thomas J. (University of California San Diego) ; Jacobs, Ryan (Levine Cancer Institute) ; Opat, Stephen (Monash University) ; Barr, Paul M. (University of Rochester Medical Center) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Trentin, Livio (University of Padova) ; Bannerji, Rajat (Rutgers Cancer Institute of New Jersey) ; Jackson, Sharon (Middlemore Hospital) ; Kuss, Bryone J. (Flinders University and Medical Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Szafer-Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ; Russell, Kristin (Pharmacyclics LLC. an AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ; Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Wierda, William G. (DepaUniversity of Texas MD Anderson Cancer Center) ; Ghia, Paolo (IRCCS Ospedale San Raffaele) ; Universitat Autònoma de Barcelona
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. [...]
2022 - 10.1182/blood.2021014488
Blood, Vol. 139 Núm. 22 (february 2022) , p. 3278-3289  
Detailed record - Creative Commons
2.
7 p, 267.3 KB Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials / Allan, John N. (Weill Cornell Medicine) ; Shanafelt, Tait (Stanford University Medical Center) ; Wiestner, Adrian (National Heart, Lung, and Blood Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; O'Brien, Susan M. (University of California Irvine) ; Li, Jianling (Pharmacyclics LLC) ; Krigsfeld, Gabriel (Pharmacyclics LLC) ; Dean, James P. (Pharmacyclics LLC) ; Ahn, Inhye E. (National Heart, Lung, and Blood Institute) ; Universitat Autònoma de Barcelona
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. [...]
2021 - 10.1111/bjh.17984
British Journal of Haematology, Vol. 196 (december 2021) , p. 947-953  
Detailed record - Creative Commons
3.
15 p, 664.9 KB Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study / Wierda, W. G. (University of Texas.) ; Allan, J. N. (Weill Cornell Medicine) ; Siddiqi, Tanya (City of Hope National Medical Center) ; Kipps, T. J. (UCSD. Moores Cancer Center) ; Opat, S. (Monash University) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Badoux, X. C. (Ministry of Health) ; Kuss, B. J. (Flinders University. Medical Centre) ; Jackson, Sharon (Middlemore Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Jacobs, R. M. D. (Levine Cancer Institute) ; Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ; Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ; Pak, Y. (Pharmacyclics LLC. AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ; Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ; Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ; Dean, James P (Pharmacyclics LLC. AbbVie Company) ; James, D. F. (Pharmacyclics LLC. AbbVie Company) ; Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ; Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ; Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865  
Detailed record - Creative Commons

See also: similar author names
1 Allan, J.
1 Allan, J. David
1 Allan, J. N.
1 Allan, John N
1 Allan, John N.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with